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HIV-1 envelopes from two series of primary isolates (from Swedish patients 5 and 6), from JR-FL and BaL (prototypic
monocyte/macrophage tropic viruses) and from HXB-2 (a prototypic T-cell-line-adapted virus), have been screened for their
ability to elicit neutralizing antibody to HIV-1. Rabbits were primed by gene gun inoculation with plasmids expressing secreted
monomeric (gp120) and oligomeric (gp140) forms of each Env. After four to six DNA immunizations administered over a 1-year
period, rabbits were boosted with 108 plaque-forming units of a mixture of seven recombinant vaccinia viruses which express
chimeric gp140 Envs (primary clade B sequences in a IIIb-related BH10 backbone). Neutralizing antibodies were assayed
against two T-cell-line-adapted viruses (MN and IIIb), two non-syncytium-inducing (NSI) and two syncytium-inducing (SI) primary
isolates, and two HIV-1-NL4-3-recombinants with patient 5 or 6 Envs (NL4-3/5A, NL4-3/6C). The DNA priming and recombinant
vaccinia virus boosting raised low titers of neutralizing antibody in 10 of 19 rabbits. The highest titers of neutralizing activity
(1:150 for MN) were raised in rabbits DNA primed with Envs from Swedish patient 5. These sera cross-neutralized IIIb and
MN but did not neutralize the primary isolates or the NL4-3 recombinant with the homologous 5A Env. Sera from rabbits primed
with the HXB-2 Env DNA were, for the most part, type-specific for neutralization of IIIb. In one of three assays, sera from
rabbits primed with plasmids expressing the JR-FL and BaL Envs had possible low titer neutralizing activity for two NSI, but
not two SI, primary isolates. Our results highlight the low immunogenic potential of the HIV-1 Env and demonstrate that different
Envs have different potentials to raise low titer neutralizing antibody. q 1997 Academic Press
INTRODUCTION that neutralizing antibody is a correlate of protection (for
review see Esparza et al., 1996). However, these subunit
A critical and as yet unrealized goal of HIV-1 vaccine vaccines have been less effective at eliciting antisera
development is the identification of an immunogen, or a which neutralize primary isolates of HIV-1 (Hanson, 1994;
combination of immunogens, which elicit broadly cross- Mascola et al., 1996; Berman et al., 1996; for reviews see
reactive neutralizing antibody for primary isolates of HIV- Moore and Ho, 1995; Esparza et al., 1996; Fenyo¨ et al.,
1. To date, HIV-1 envelope (Env)-based vaccines have 1996; Kent and Robinson, 1996) and have not appeared
been derived from T-cell-line-adapted strains of HIV-1 to prevent infection in human clinical trials (Kahn et al.,
which are not typical of the primary isolates transmitted 1995; McElrath et al., 1996; for review see Esparza et al.,
in the ongoing global epidemic (WHO Network for HIV 1996). An ideal HIV-1 vaccine would elicit antisera which
Isolation and Characterization, 1994; for reviews see neutralize multiple primary isolates, providing protection
Moore and Ho, 1995; Esparza et al., 1996; Subbarao and across strain, and perhaps clade, boundaries (WHO Net-
Schochetman, 1996). Subunit vaccines derived from T- work for HIV Isolation and Characterization, 1994; Moore
cell-line-adapted viruses have protected primates from et al., 1996; reviewed by Korber et al., 1995; Subbarao
challenge with adapted viruses, have elicited antibody and Schochetman, 1996; Esparza et al., 1996).
which neutralizes adapted viruses, and have suggested In a recent study we used DNA immunizations in rab-
bits to investigate the immunogenicity of a series of se-
quential primary isolate Envs from two Swedish patients1 Each of these authors contributed equally to the study.
2 Current address: Department of Microbiology, The University of (von Gegerfelt et al., 1991; Mustafa et al., in press). Multi-
Texas at Austin, Austin, TX 78712. ple immunizations with plasmids expressing secreted
3 Current address: Department of Medicine, University of Massachu- gp120 and gp140 forms of these Envs elicited varyingsetts Medical School, 55 Lake Avenue North, Worcester, MA 01655.
low titers of ELISA antibody (0.1–8.6 mg of Env-specific4 To whom correspondence and reprint requests should be ad-
dressed. IgG/ml of sera). Titers were affected by the form and
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source (or origin) of Env, but were not related to the MATERIALS AND METHODS
growth characteristics conferred on recombinant viruses
Animalsby these envs (Mustafa et al., in press).
In this study we have screened these, as well as Female New Zealand White rabbits, 8–10 weeks old
additional DNA-primed rabbit sera, for neutralization and 4–5 pounds each, were purchased from Millbrook
of T-cell-line-adapted strains and primary isolates of Farms (Amherst, MA) and housed in accordance with
HIV-1. We have also evaluated the ability of a mixture USDA regulations. Rabbits were anesthetized using a 1:1
of recombinant vaccinia viruses expressing gp140 (v/v) mixture of ketamine:anased, and they were bled by
Envs to boost DNA-primed neutralizing responses. The ear vein puncture.
Envs used to DNA prime rabbits represent all of the
currently defined growth phenotypes for HIV-1 and in- Plasmids
clude: a prototypic T-cell-line-adapted Env (HXB-2)
Vaccine plasmids and recombinant HIV-1 plasmids(Shaw et al., 1984); two prototypic monocyte/macro-
bearing the Swedish patient env’s are described by Mus-phage-tropic Envs (JR-FL and BaL) (O’Brien et al., 1990;
tafa et al. (in press) (see also Table 1). Plasmids carryingGartner et al., 1986); and serial primary Envs molecu-
the BaL env (pBaLc) and the JR-FL env (pSVDFL112-1)larly cloned from Swedish patients 5 and 6 (Mustafa
were obtained from Dr. Bryan Cullen, Duke Universityet al., in press). Recombinant vaccinia viruses were
School of Medicine and Dr. Irwin Chen, University ofused to boost antibody responses because they repre-
California, Los Angeles, respectively. A plasmid express-sented a needed source of oligomeric gp140s for pri-
ing human growth hormone (pWR61602) was providedmary Envs, and because recombinant vaccinia viruses,
by Dr. Joel Haynes of Geniva Inc. (Middleton, WI).despite their relatively weak ability to raise antibody
pJW4303 was provided by Dr. James Mullins of the Uni-responses, can be highly effective at boosting DNA-
versity of Washington at Seattle.primed responses (Leong et al., 1995; Fuller et al., in
press). A mixture of recombinant vaccinia viruses was
Construction and expression of JR-FL and BaL env-used to optimize the chance of raising a broad neu-
expressing plasmidstralizing antibody response. This mixture included one
T-cell-line-adapted Env and six different chimeric Envs Plasmids expressing JR-FL and BaL env constructs
whose variable sequences had been derived directly were created by cloning PCR-amplified env fragments
from the blood of individuals infected with clade B HIV- from pBaLc and pSVDFL112-1 in-frame with the synthetic
1 (Rencher et al., 1996). Neutralization assays evalu- tPA leader of the eukaryotic expression vector pJW4303
ated activity against two prototypic T-cell-line-adapted (for details see Mustafa et al., in press). pJW4303 sup-
viruses (IIIb and MN), two NSI (W25798 and P59432) ports Rev-independent expression of Env (Chapman et
and two SI primary isolates (V89872 and V67970) (Mon- al., 1991). Plasmids were propagated in Escherichia coli
tefiori et al., 1996), and two recombinants carrying pa- HB101, and DNA was prepared using mini-prep and
tient 5 or 6 Envs (NL4-3/5A and NL4-3/5C) (Mustafa et Giga-prep kits (Qiagen, Chatsworth, CA). Expression of
al., in press). JR-FL and BaL Env constructs was examined by antigen-
Unlike most viral infections, HIV-1 infections do not capture ELISA and Western blotting following transient
raise high titers of neutralizing antibody (Moore and transfection of Cos-1 cells, as described by Mustafa et
Ho, 1995; Moore et al., 1996; Fenyo¨ et al., 1996; Monte- al. (in press). Cotransfection of human growth hormone-
fiori et al., 1996). In general, patient sera have better expressing plasmid (pWR61602) was used to monitor
titers of neutralizing activity for T-cell-line-adapted vi- transfection efficiency.
ruses than patient isolates (including the autologous
isolate). For example sera from 10 – 12 asymptomatic Gene gun immunization of rabbits
HIV-1 infected individuals had mean titers of 680 { 408
for MN, 345 { 297 for IIIb, and undetectable activity for DNA was precipitated onto 0.95 or 1- to 3-mm gold
beads (Degussa, South Plainfield, NJ) with 100 mM sper-the primary isolates used in this study (Montefiori et
al., 1996). Occasional sera have broad activity for both midine and 2.5 M CaCl2 at ratios of 0.25–1.25 mg of DNA
per 0.5 mg gold shot (Eisenbraun et al., 1993). Betweenpatient and primary isolates; such a serum, D75899,
has titers of 951 and 2279 for MN and IIIb, respectively, 6 and 40 shots of DNA-coated gold beads were delivered
to nonoverlapping areas of shaved abdominal skin ofand titers ranging from 8 to 64 for the four primary
isolates used in the study (Zhou and Montefiori, 1997). anesthetized rabbits with the helium-discharge Accell II
gene gun (Geniva) at 300–400 pounds per square inch.Thus neutralizing antibody for primary isolates can be
raised. The challenge is to identify the Envs, or the Sera were collected just prior to each DNA immuniza-
tion, and roughly 2, 4, and 8 weeks following each immu-epitopes, which can be used to raise such broad neu-
tralizing antibody. nization.
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Boosting of rabbits with recombinant vaccinia-gp140 ity. For most rabbits this background was approximately
0.01 mg/ml.
After receiving four to six DNA immunizations, selected
rabbits were boosted by six intradermal injections of 50 Neutralizing antibody assays
ml each, containing a total of 108 plaque-forming units
(PFU) of a mixture of seven recombinant vaccinia viruses Antibody-mediated neutralization of HIV-1 IIIB and MN
(referred to as vv-gp140). One recombinant expressed was measured in an MT-2 cell-killing assay as described
the gp140 form of BH10 Env (a IIIb variant). Four ex- previously (Montefiori et al., 1988). Briefly, cell-free virus
pressed chimeric BH10 gp140 constructs whose V1-V3 (50 ml containing 108 TCID50 of virus) was added to
regions were replaced with those from four different HIV- multiple dilutions of serum samples in 100 ml of growth
1-infected individuals from the United States, and two medium in triplicate wells of 96-well microtiter plates
expressed chimeric BH10 gp140 whose V1-V5 regions, coated with poly-L-lysine and incubated at 377 for 1 hr
and a portion of gp41, were replaced with those of two before MT-2 cells were added (105 cells in 100 ml added
additional HIV-1-infected individuals (Rencher et al., in per well). Cell densities were reduced and the medium
press; Ryan et al., 1997). Vaccinia virus-boosted rabbits was replaced after 3 days of incubation when necessary.
were housed in a Biosafety level 2 facility. Mild inflamma- Neutralization was measured by staining viable cells with
tion and scabs indicative of vaccinia infection were ob- Finter’s neutral red when cytopathic effects in control
served at the site of vaccinia inoculation. Sera were col- wells were70% but less than 100%. Percentage protec-
lected at 2, 4, 8, and 12 weeks after the vv-gp140 boost tion was determined by calculating the difference in ab-
and were incubated for 30 min at 567 to inactivate vac- sorption (A540) between test wells (cells/ plasma sample
cinia virus. / virus) and virus control wells (cells / virus) and divid-
ing this result by the difference in absorption between
cell control wells (cells only) and virus control wells (virusDetermination of HIV-1 Env-specific antibody (ELISA)
only). Neutralizing titers are expressed as the reciprocaltiters
of the plasma dilution required to protect at least 50% of
cells from virus-induced killing.The anti-Env titers of rabbit sera were assayed using
an ELISA which employed concanavalin A to capture Antibody-mediated neutralization of primary isolates
was measured in phytohemagglutinin-stimulated hu-Env, which was then used as the solid-phase antigen
(Robinson et al., 1990). Sera collected following DNA man peripheral blood mononuclear cells (PHA-PBMC)
as described (Montefiori et al., 1996) using p24 immu-immunizations were assayed using the mixture of gp120
and gp140 forms of the BH8 Env (a IIIb variant) produced noassay (DuPont, Wilmington, DE) to quantify virus pro-
duction. The primary isolates W25798, P59423, V89872,by the recombinant vaccinia virus vCB-14 (Earl et al.,
1994). vCB-14 produces a gp140 form of the BH-8 Env and V67970 used for neutralization assays were sec-
ond-passage stocks grown in human PHA-PBMCthat partially dissociates to give rise to a mixture of gp120
as well as oligomeric forms of the expressed gp140. Sera (Montefiori et al., 1996). Their SI or NSI phenotype was
determined in human PHA-PBMC and MT-2 cells. Forcollected following vv-gp140 boosting were assayed us-
ing recombinant gp120 (rgp120-IIIb; Intracel, Cambridge neutralization assays, virus/serum mixtures were incu-
bated at 377 for 1 hr and then added to triplicate wellsMA). This ensured that anti-vaccinia virus antibodies did
not interfere with determination of anti-Env antibody titers of 96-well U-bottom plates containing PHA-PBMC from
a single HIV-1 negative donor. The TCID50 used forin boosted rabbits. These two assays gave identical re-
sults for sera collected before and after DNA priming, the primary isolates were: W25798 (170), P59423 (560),
V89872 (1300), and V67970 (9400). Cells were incu-but discordant activity after the boost (reflecting anti-
vaccinia antibody) (data not shown). A standard curve bated with the virus/serum mixtures for 3 hr at 377 and
then washed 3 times with 200 ml of growth medium towas constructed using sera pooled from rabbits immu-
nized with a plasmid expressing HXB-2 gp120, whose remove the virus inoculum and antibodies. Washed
cells were suspended in 250 ml of IL-2 growth mediumanti-Env IgG concentrations had been approximated. All
samples and dilutions were assayed in duplicate wells, and incubated in 96-well flat-bottom plates for the du-
ration. Cell suspensions (25 ml) were collected on aand a standard curve was included on each ELISA plate.
Blank values were subtracted, standard curves were fit- daily basis for p24 quantification; this volume was re-
placed with 25 ml of fresh IL-2 growth medium at eachted using 4-parameter equations, and sample concentra-
tions were interpolated, as micrograms per milliliter of collection. The amount of p24 produced in the absence
of test sera (i.e., virus control) was determined aftersera, using SOFTmax 2.3 software (Molecular Devices,
Sunnyvale CA). ELISAs performed with both solid-phase each daily sampling and was used to construct a virus
replication curve. Reductions in p24 production in testantigens had sensitivities of roughly 5 ng/ml. Different
rabbits had different background levels of ELISA reactiv- wells were measured just prior to peak p24 production
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TABLE 1
HIV-1 Primary Isolate envs
Expression in Cos cellsa
Isolate Clone Source Growth phenotype gp120 gp140
5Ab IK-51 Patient 5 PBMC Rapid growth on PBMC and T-cell lines 62.3 (93%) 36.8 (64%)
5Bb A1-1-52 Patient 5 PBMC Poor growth on PBMC, no growth on T-cell lines 1.8 (93%) 12.3 (26%)
6Ab 3C-61 Patient 6 PBMC Moderate growth on PBMC, poor growth on T-cell lines 41.6 (93%) 43.3 (30%)
6Cb A4-1-63 Patient 6 PBMC Rapid growth on PBMC and T-cell lines 15.9 (95%) 24.2 (18%)
6Db 4A-64 Patient 6 PBMC Rapid growth on PBMC and T-cell lines 44.1 (95%) 25.1 (27%)
BaLc pBaLc Pediatric/lung Monocyte/macrophage-tropic isolate 0.3 (100%) 24.7 (7.1%)
JR-FLd pSVDFL112-1 Frontal lobe Monocyte/macrophage-tropic isolate; sequence 23.3 (87%) 36.8 (15%)
resembles the clade B consensus
HXB-2e HXB-2 Laboratory strain T-cell line-adapted virus from the IIIb stock which was 11.9 (92%) 14.6 (50%)
selected for chronic viral production on H9 cells
a Total ng of Env protein per transfection (percentage of protein secreted into the medium)
b Data for isolates from Swedish patients 5 and 6 was adapted from Mustafa et al. (in press).
c Gartner et al. (1986).
d O’Brien et al. (1990).
e Shaw et al. (1984).
in virus control wells (usually 3 – 6 days). Serum sam- 15% of JR-FL gp140 Env protein) (Table 1 and Mustafa
et al., in press).ples were considered positive for primary isolate neu-
tralization if they caused 80% reduction in p24. All Immunization with plasmids expressing BaL and JR-
FL Envs elicited very low titers of ELISA antibody (Fig.serum samples were heat-inactivated at 567 for 1 hr
prior to use. Neutralization of recombinant NL4-3/env 1). Positive ELISA titers rose and fell with successive
DNA priming (for example, see Fig. 1, JR-FL gp120 immu-viruses was similarly assayed on PBMCs with the ex-
ceptions that assays were conducted in quadruplicate nizations). However, antibody titers, both postimmuniza-
tion peaks and interimmunization troughs, tended to in-for TCID50 of 100, residual virus was washed from
cultures at 1 day postinfection, viral replication was crease with successive DNA immunizations (for exam-
ple, see Fig. 1, BaL gp120 immunizations). As a whole,assessed at 4 days postinfection, and assays for virus
used an HIV-Ig (Abbott Laboratories, Abbott Park IL)- the ELISA titers for JR-FL and BaL were in the lower
range of titers elicited by DNA immunization with Swed-based antigen capture ELISA (Mustafa et al., in press).
ish patient Envs or the HXB-2 T-cell-line-adapted Env
(Table 2) (Mustafa et al., in press). In keeping with priorRESULTS
results, gp120-expressing plasmids were more immuno-
Expression and immunogenicity of plasmids
genic than those which express gp140 (Table 2) (Mustafa
expressing JR-FL and BaL envs
et al., in press).
The origin and replication phenotypes of the Enve-
lope glycoproteins used in this study are summarized Recombinant vaccinia virus (vv-gp140) boosting
in Table 1. Plasmids expressing gp120 and gp140
forms of BaL and JR-FL Envs were made to complement In an attempt to increase antibody titers, rabbits with
ELISA responses to DNA priming were boosted with aplasmids which express these forms of Swedish pri-
mary isolate Envs as described by Mustafa et al. (in mixture of seven recombinant vaccinia viruses which ex-
press one IIIb, and six chimeric gp140 Envs containingpress). Transient transfection of Cos cells revealed
that three of four of the JR-FL and BaL constructs were clade B variable regions (vv-gp140). The vv-gp140 boost-
ing was most effective at increasing the ELISA titers ofexpressed at levels comparable to those of other Env-
expressing plasmids (23 – 62 ng per transfection; Mus- rabbits primed with plasmids expressing the gp140 form
of the Swedish patient Envs (Table 2). In these booststafa et al., in press). However, the gp120 form of the
BaL Env was expressed at much lower levels (0.3 ng ELISA titers were increased by 5- to 15-fold over the
peak ELISA value that had been achieved by DNA immu-per transfection). In keeping with previous studies,
nearly all of the gp120 protein was secreted into cul- nization (Table 2, Fig. 1). This may reflect the conserva-
tion of epitopes between the primary isolate gp140 primeture supernate (100% of BaL gp120 and 87% of JR-FL
gp120 Env protein), while much less of the correspond- and boost. It is also possible that the vv-gp140 boost
preferentially increased the titers of the gp140 primeding gp140 proteins was secreted (7% of BaL gp140 and
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FIG. 1. Temporal antibody response to DNA-priming and vv-gp140 boosting. Groups of three female NZW rabbits were immunized with DNA
using an Accell helium-pulse gene gun according to this schedule: Week 1, 6 shots of 1.25 mg each; Weeks 10 and 24, 40 shots of 1.25 mg each;
Week 40, 36 shots of 0.25 mg each. At Week 58 selected rabbits were immunized with 108 PFU of vv-gp140 administered in 6 intradermal injections
of 50 ml each. DNA immunizations are indicated by the four narrow and dotted vertical lines, while the vv-gp140 boost is indicated by the boldface
dotted vertical line. Antibody titers of sera collected after DNA immunizations are represented by open symbols, while titers of sera collected after
the vv-gp140 boost are represented by corresponding filled symbols. BaL gp120 group: R58 (circles), R59 (squares), and R60 (triangles). BaL gp140
group: R70 (circles), R71 (squares), and R72 (triangles). JR-FL gp120 group: R55 (circles), R56 (squares), and R57 (triangles). JR-FL gp140 group:
R67 (circles), R68 (squares), and R89 (triangles).
rabbits because the primed titers were lower in gp140 exhibited neutralizing antibody for MN after vv-gp140
boosting had preboost neutralizing antibody for MN. Inthan gp120 immunized rabbits. However, we consider
this explanation unlikely because the titers of gp120- these 3 rabbits DNA-primed neutralizing titers were two-
to threefold lower than the vv-gp140 boosted neutralizingprimed responses (both before and after boosting) were
far below the maximum levels of specific antiserum that titers. Six of the 8 MN-neutralizing sera also neutralized
IIIb. Serum from 1 of 4 control rabbits immunized withcan be achieved in prime/boost protocols for Env (work
in progress). The vv-gp140 boosting also increased the vv-gp140 (without prior Env DNA-priming) had low titer
neutralizing activity for MN. None of these control serapersistence of some ELISA titers (e.g., JR-FL gp140 rabbit
56 (squares); Fig. 1). neutralized IIIb (Table 2).
Neutralization of primary isolates of HIV-1 by vv-Neutralizing antibody for T-cell-line-adapted viruses
following vv-gp140 boosting gp140-boosted rabbit sera
None of the sera showed consistent neutralizing activityThe vv-gp140 boost increased the frequency and titer
of antibody which neutralized two T-cell-line-adapted vi- for the primary isolates. However, two of the sera elicited
by DNA priming with the monocyte/macrophage-tropicruses (MN and IIIb). After boosting, sera from 8 of 19
rabbits exhibited low to moderate titers of neutralizing gp140 form of JR-FL and BaL Envs exhibited low titers of
neutralizing activity for the two NSI primary isolates in oneactivity for MN (1:14–1:148). Only 3 of the 8 rabbits which
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TABLE 2




Peak vv-gp140 DNA-primed boosted boosted
Peak DNA-primed boosted titer Fold increase MN titer MN titer Fold increase IIIb titer
Plasmid Rabbit titer (mg/ml) (mg/ml) in peak titer (1/NAb) (1/NAb) in MN titer (1/NAb)
gp120
HXB-2 R15 9.7 { 1.6 12.8 { 3.7 1  39
R16 8.4 { 3.2 12.3 { 1.4 1 14 23
5A R41 20.5 { 2.2 54.6 { 7.2 3 44 148 3.4 
5B R44 2.2 { 0.4 6.1 { 0.8 3  
R45 1.9 { 0.3 3.3 { 0.6 2 28 144 5.1 121
6A R47 2.0 { 0.4 2.7 { 0.1 1  
BaL R60 2.4 { 0.8 2.3 { 0.4 1  
JR-FL R56 2.1 { 0.5 6.5 { 3.3 3  
gp140
HXB-2 R18 3.5 { 0.7 2.1 { 0.5 1  
R19 2.0 { 0.3 1.8 { 0.2 1  28
5A R29 1.3 { 0.4 6.7 { 1.0 5  146 14.6 52
R30 1.6 { 0.5 34.4 { 7.2 15 31 114 3.7 130
5B R88 1.1 { 0.2 7.2 { 1.8 6  100 10.0 22
6A R33 2.2 { 0.6 17.3 { 0.7 13  17 1.7 18
BaL R70 0.1 3.2 { 0.9 n.a  
R71 0.5 { 0.1 1.0 { 0.2 2   
R72 0.1 0.5 { 0.1 n.a.  
JR-FL R67 0.2 { 0.1 1.0 { 0.2 5  22 2.2 
R68 0.1 { 0.1 0.3 { 0.1 3   
Controls
pJW4303 R20 0.1 0.4 { 0.1 n.a.   
R21 0.1 0.3 { 0.1 n.a.  
Prebleed
Naive R124 0.1 0.1 n.a.   
R125 0.1 0.2 { 0.1 n.a.  40 4.0 
Note. ELISA values are mean { SD for the peak antibody titer induced by the DNA immunizations and the vv-gp140 boost. Neutralization titers
(1/NAb) are for sera taken at peak DNA-elicited ELISA values and at 2 weeks after the vv-gp140 boost. n.a., not applicable. ELISA responses of
0.1 mg/ml were not considered significant. , neutralizing titer of 10.
assay (Table 3, experiment 1). In this assay, 1:10 dilutions primary isolates, demonstrating that these viruses can be
neutralized (Table 3).of vv-gp140-boosted serum from one of two rabbits primed
with BaL gp140 plasmid (R71) and one of two rabbits
Neutralization of recombinant HIV-1 bearing envs
primed with JR-FL gp140 plasmid (R68) reduced p24 levels
from Swedish patients 5 and 6
of the two NSI primary isolates by 70–94%. These two
The vv-gp140 boosted sera did not neutralize the NL4-rabbits were the rabbits that had been most effectively
3/5A and 6C recombinants in which the env gene wasprimed by the DNA immunizations with the BaL and JR-
derived from patient 5 and 6 primary isolates (data notFL Envs (Table 2). None of the other rabbit sera achieved
shown). However, these recombinant viruses could be neu-similar reductions in the replication of the primary isolates.
tralized by pooled immunoglobulin from HIV-1-infected pa-In two repeated assays in which preimmune as well as
tients (HIV-Ig) and the D75899 patient serum with unusuallyimmune sera from rabbits R71 and R68 were tested for
broad neutralizing antibody (data not shown).neutralizing activity, none of the sera reduced virus repli-
cation by more than 50% (for example, see Table 3, Experi- DISCUSSION
ment 2). Thus the potential low level neutralizing activity
Raising of low titers of neutralizing antibody by DNAwas scored in only one of three replicate assays. D75899,
immunization and recombinant vaccinia virus-boostinga patient sera with unusually broad neutralizing activity
for primary isolates (Zhou and Montefiori, 1997) exhibited Our data demonstrate that neither our DNA immuniza-
tion nor DNA priming and recombinant vaccinia virusneutralizing titers from 8 to 64 against the four tested
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TABLE 3
Neutralization of Primary Isolates of HIV-1 Following vv-gp140 Boosting
W25798 P59432 V89872 V67970
Plasmid Rabbit Bleed (NSI) (NSI) (SI) (SI)
Experiment 1
gp120
5A R41 17 14 { 11 35 { 14 0 6 { 16
5B R45 17 0 37 { 26 0 26 { 26
6A R47 17 33 { 23 23 { 18 0 0
gp140
5A R29 17 57 { 26 35 { 16 8 { 38 59 { 19
R30 17 30 { 32 33 { 10 0 0
5B R88 17 48 { 5 36 { 30 39 { 1 39 { 14
BaL R70 17 0 0 0 0
R71 17 93 { 1 84 { 5 35 { 11 49 { 3
JR-FL R67 17 59 { 10 12 { 30 8 { 23 48 { 17
R68 17 90 { 8 77 { 8 30 { 8 58 { 12
Experiment 2
gp140
BaL R71 1 0 0
18 0 0
JR-FL R67 1 0 0
18 9 { 20 0
R68 1 0 0
18 21 { 10 20 { 7
Positive control
D75899 1:8 1:16 1:32 1:64
Note. Values are percentage reduction in p24 synthesis { standard deviation. 1:10 dilutions of sera were assayed before immunization (bleed
1), or at 2 (bleed 17) or 4 weeks (bleed 18) after the vv-gp140 boost. Neutralization was defined as a 80% reduction in p24 values relative to p24
production in the absence of test serum. Levels of p24 production in the absence of test sera were 22.5 ng/ml for W25798, 24.0 ng/ml for P59423,
17.1 ng/ml for V89872, and 26.9 ng/ml for V67970 in experiment 1; and 9.4 ng/ml for W25978 and 9.2 ng/ml for P59423 in experiment 2. The positive
control, D75899, is a patient serum with unusually broad titers of neutralizing activity for primary isolates. The titers for D75899 are the end point
dilution scoring for neutralization.
boosting raised high titers of neutralizing antibody for (eliciting 20 mg of hemagglutinin-specific antibody per
milliliter), a single boost with H1-expressing recombinantHIV-1. Four to six DNA immunizations over the course of
a year raised maximum ELISA titers of 10 mg of Env- fowl pox can increase titers of specific antibody to 1
mg/ml. Thus, in similar prime/boost regimens, the HIV-1specific antibody per milliliter of serum, and maximum
neutralizing titers of 1:50 for MN and IIIb. The single Env is much less immunogenic than the influenza hem-
agglutinin.vv-gp140 boost increased both the titer and the frequency
of ELISA and neutralizing antibodies (Table 2). However, HIV-1, which maintains chronic infections by continu-
ous replication in the face of strong immune responseseven after the boost, both ELISA and neutralizing titers
remained low, with peak ELISA values never exceeding (Ho et al., 1995; Wei et al., 1995), may have developed
‘‘nonimmunogenic’’ envelope glycoproteins in response20 mg of Env specific antibody per milliliter, and peak
neutralizing titers never exceeding 1:150 for MN or IIIb. to immune pressure. This nonimmunogenic nature of Env
may reduce the ability of immunization protocols suchThese neutralizing titers are lower than those observed
in many asymptomatic HIV-1-positive individuals whose as DNA or recombinant vaccinia virus that express low
levels of protein to raise antibody (for review, see Rob-mean titers of neutralizing activity are 680 { 408 for MN,
and 345 { 297 for IIIb (Montefiori et al., 1996). inson, in press). Indeed, the use of a single boost of
100 mg of recombinant Env protein can increase low-titerThe low anti-Env antibody titers elicited by DNA prim-
ing and vv-gp140 boosting contrast sharply with similar DNA-primed responses to the HXB-2 Env to ELISA titers
of 100 mg/ml, and to neutralization titers of 1000 forstudies using the influenza hemagglutinin. Single inocu-
lations of a DNA expressing the hemagglutinin H1 raise IIIb (work in progress, see also Robinson, in press).
These more successful protein boosts use much morecomparable titers of neutralizing antibody to those ob-
served in sublethally infected animals (Robinson et al., protein than is expressed after DNA immunization, where
10 ng of Env is expressed per gene gun target (Fuller1995). Furthermore, following low-dose DNA priming
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and Haynes, 1994; Lu et al., 1995) and less than 1 mg of mary virus epitopes represented in the boosting gp140s.
This would be consistent with the most effective boostingEnv is likely to be expressed by the recombinant pox
virus boosts (Fuerst et al., 1987). Thus the poorly immuno- occurring in rabbits primed with the patient 5 and 6
gp140s (Table 2). Future studies will focus on boostinggenic HIV-1 Env may require protein immunizations (or
boosts) to achieve high titer antibody responses. the responses raised by selected Envs (5A, JR-FL, and
BaL) with homologous vv-gp140, or homologous oligo-
meric protein. Only by increasing the titers of these anti-Different patterns of neutralizing responses for
body responses will differences in the specificity of neu-different Envs
tralization be able to be rigorously evaluated.
Despite the low titers of neutralizing activity, our re-
The form of Env affects neutralizing antibodysults do reveal that different Envs prime different patterns
responsesof neutralizing antibody (Tables 2 and 3). The HXB-2 T-
cell-line-adapted Env appeared to prime largely type-spe- Within the small number of animals tested, neutralizing
cific neutralizing activity for IIIb. By contrast, the patient antibody was most frequently observed in rabbits primed
5 Envs (especially the gp140 form) appeared to prime with gp140-expressing plasmids (Tables 2 and 3). This
more broadly cross-reactive neutralizing activity for T- is consistent with studies which have shown that mono-
cell-line-adapted viruses. Indeed, the patient 5 Envs were meric and oligomeric forms of Env expose distinct epi-
more effective than the HXB-2 Env at priming neutralizing topes (Broder et al., 1994; Earl et al., 1994; Stamatatos
antibody for IIIb (Table 2). None of the Envs raised signifi- and Cheng-Mayer, 1995) and that the ability of antibody
cant titers of neutralizing antibody for the patient isolates to neutralize HIV-1 is predicted by binding to oligomeric
(Table 3). Low levels of neutralizing antibody may have but not monomeric forms of Env (Moore et al., 1995).
been induced by the JR-FL and BaL gp140s (Table 3).
Provocatively, this low-level activity was detected against Future importance of DNA primes and recombinant
the NSI but not the SI primary isolates and therefore may vaccinia virus boosts
have been specific for isolates that share the monocyte/
Despite the low titers of neutralizing antibody raisedmacrophage tropism of JR-FL and BaL.
in this pilot study, DNA priming, or DNA priming andThe above low-titer patterns could be consistent with
recombinant vaccinia virus boosting, merits further evalu-some patterns of neutralization being a function of the
ation. Both DNA priming and vaccinia boosting producecytotropism/coreceptor usage of the immunizing Env
the native forms of proteins in host cells. Thus, both of(Feng et al., 1996; Alkhatib et al., 1996; Dragic et al., 1996;
these methods of immunization should elicit antibodyDeng et al., 1996; Doranz et al., 1996; Choe et al., 1996;
against the conformational epitopes that are the primaryZhang et al., 1996; see Robinson, in press). For example,
targets for primary isolate neutralization (Van Cott et al.,the T-cell tropic Env of patient 5A raised neutralizing
1995a,b; Moore et al., 1995, 1996). Also, by producingantibody capable of neutralizing T-cell-line-adapted
proteins in the immunized host, both of these methods ofEnvs. These Envs use the CXCR-4 coreceptor (Feng et
immunization introduce Env into major histocompatibilityal., 1996; Doranz et al., 1996; Choe et al., 1996; Zhang et
class I presentation pathways and thus have the poten-al., 1996). By contrast, the JR-FL and BaL Envs may have
tial for eliciting cytolytic T-cell responses (Fuller andraised low-titer activity for monocyte-macrophage tropic
Haynes, 1994; Lu et al., 1995; Okuda et al., 1995; Yasu-Envs. These use the CCR-5, but not the CXCR-4 corecep-
tomi et al., 1996; Boyer et al., 1996). Cytolytic T-cells aretor (Alkhatib et al., 1996; Dragic et al., 1996; Deng et al.,
likely to be important mediators for the reduction of viral1996; Doranz et al., 1996; Choe et al., 1996; Zhang et al.,
loads in infected patients (Koup et al., 1994). Finally, the1996).
efficiency of DNA immunizations and recombinant poxWe consider that the differences in immunogenicity of
virus boosts may be improved by priming with DNAs thatthe different Envs reflect true qualitative differences in
optimize the immunogenicity of Env and by boosting withthe ability of the different Envs to prime antibody re-
recombinant vaccinia viruses that express homologoussponses. Most Envs were expressed at fairly similar lev-
Envs, or increase Env expression by the use of moreels in COS cells, with differences in levels of expression
efficient promoters (Fuerst et al., 1987) and the removalnot necessarily affecting immunogenicity in our multi-
of vaccinia virus translational stop sites within env se-boost protocol (note low level of expression but good
quences (Earl et al., 1990).immunogenicity of the 5B gp120; Tables 1 and 2). Thus
Envs that failed to raise neutralizing antibody may repre-
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